goodrx glp-1 has savings on the newest GLP-1s for weight loss. Get the new oral medication Foundayo™ (orfoglipron) and new multi-dose Zepbound® KwikPen® starting at just $149. Check GoodRx.com to learn more GoodRx, Novo Nordisk team to

Target fasting glucose levels The ADA suggests a target fasting glucose level of 80 130 mg/dL for many (non-pregnant) adults with diabetes (ADA 2021a)

It's a communication tool

Porras G, Di Matteo V, Fracasso C, et al

[53] Tirzepatide's efficacy for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight who had at least one weight-related condition

Tirzepatide, on the other hand, is a newer medication that also targets both GLP-1 and GIP receptors but has gained significant attention due to its impressive results in clinical trials and recent FDA approval for type 2 diabetes treatment